n-methylisoindigotin has been researched along with deoxycytidine in 1 studies
| Studies (n-methylisoindigotin) | Trials (n-methylisoindigotin) | Recent Studies (post-2010) (n-methylisoindigotin) | Studies (deoxycytidine) | Trials (deoxycytidine) | Recent Studies (post-2010) (deoxycytidine) |
|---|---|---|---|---|---|
| 34 | 0 | 11 | 18,160 | 4,652 | 8,898 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alborzinia, H; Cheng, X; Duvaci, T; Eisenbrand, G; Fredebohm, J; Ghafoory, S; Hafezi, M; Hoheisel, JD; Holenya, P; Kim, JY; Mehrabi, A; Merz, KH; Rafiee, R; Saffari, A; Theobald, J; Wölfl, S | 1 |
1 other study(ies) available for n-methylisoindigotin and deoxycytidine
| Article | Year |
|---|---|
Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Indoles; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases | 2016 |